Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: A review of clinical trial results

Current Opinion in Oncology

Volumn 24, Issue 4, 2012, Pages 419-424

  Malhotra, Binu ^a   Schuetze, Scott M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

dermatofibrosarcoma protuberans; imatinib; platelet derived growth factor; platelet derived growth factor receptor

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA; IMATINIB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; CANCER RECURRENCE; CANCER SURGERY; CHROMOSOME 17; CHROMOSOME 22; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DERMATOFIBROSARCOMA PROTUBERANS; GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; METASTASIS; PATHOLOGY; PHOSPHORYLATION; PHYSICIAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DERMATOFIBROSARCOMA; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SKIN NEOPLASMS;

EID: 84862117864     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328353d78d     Document Type: Review

References (46)

1. Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004; 30:341-345. (Pubitemid 38425655)
2. Mendenhall WM, Zlotecki RA, Scarborough MT, et al. Dermatofibroma protruberans. Cancer 2004; 101:2503-2508.
3. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007; 56:968.
4. Bowne WB, Antonescu CR, Leung DH. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000; 88:2711.
5. Laskin WB. Dermatofibrosarcoma protuberans. CA Cancer J Clin 1992; 42:116-125.
6. Shmookler BM, Enzinger FM, Weiss SW. Giant cell fibroblastoma. A juvenile form of dermatofibrosarcoma protuberans. Cancer 1989; 64:2154-2161. (Pubitemid 19280419)
7. Terrier-Lacombe MJ, Guillou L, Maire G, et al. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2003; 27:27-39. (Pubitemid 36014896)
8. Love WE, Keiler SA, Tamburro JE, et al. Surgical management of congenital dermatofibrosarcoma protuberans. J Am Acad Dermatol 2009; 61:1014.
9. Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997; 15:95-98. (Pubitemid 27014958)
10. Kikuchi K, Soma Y, Fujimoto M, et al. Dermatofibrosarcoma protuberans: increased growth response to platelet-derived growth factor BB in cell culture. Biochem Biophys Res Commun 1993; 196:409-415. (Pubitemid 23309523)
11. Greco A, Roccato E, Miranda C, et al. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer 2001; 92:354-360. (Pubitemid 32249711)
12. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001; 61:5778-5783. (Pubitemid 32769094)
13. Lindner NJ, Scarborough MT, Powell GJ, et al. Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. Eur J Surg Oncol 1999; 25:392-397. (Pubitemid 29364226)
14. Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996; 35:355-374; quiz 375-356. (Pubitemid 126690414)
15. Elgart GW, Hanly A, Busso M, et al. Bednar tumor (pigmented dermatofibrosarcoma protuberans) occurring in a site of prior immunization: immunochemical findings and therapy. J Am Acad Dermatol 1999; 40:315-317. (Pubitemid 29076088)
16. Parlette LE, Smith CK, Germain LM, et al. Accelerated growth of dermatofibrosarcoma protuberans during pregnancy. J Am Acad Dermatol 1999; 41:778-783.
17. Har-Shai Y, Govrin-Yehudain J, Ullmann Y, et al. Dermatofibrosarcoma protuberans appearing during pregnancy. Ann Plast Surg 1993; 31:91-93. (Pubitemid 23204457)
18. Rutgers EJ, Kroon BB, Albus-Lutter CE, Gortzak E. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 1992; 18:241-248.
19. Enzinger FM, Weiss SW. Fibrohistiocytic tumors of intermediate malignancy. In Stamathis G. Soft tissue tumors. St. Louis: Mosby; 1988. pp. 252-268.
20. Taylor HB, Helwig EB. Dermatofibrosarcoma protuberans. A study of 115 cases. Cancer 1962; 15:717-725.
21. Haycox CL, Odland PB, Olbricht SM, et al. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. J Am Acad Dermatol 1997; 37:438.
22. West RB, Harvell J, Linn SC, et al. Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans. Am J Surg Pathol 2004; 28:1063-1069. (Pubitemid 38971432)
23. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008; 39:184-193.
24. Shimizu A, O'Brien KP, Sjoblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999; 59:3719-3723. (Pubitemid 29381878)
25. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. Am J Surg Pathol 2000; 24:1125.
26. Voth H, Landsberg J, Hinz T. Management of dermatofibrosarcoma protuberans with fibrosarcomatous transformation: an evidence-based review of the literature. Eur Acad Dermatol Venereol 2011; 25:1385-1391.
27. Elgart GW, Hanly A, Busso M, et al. Bednar occurring in a site of prior immunization: immunochemical findings and therapy. J Am Acad Dermatol 1999; 40 (2 Pt 2):315.
28. Reimann JD, Fletcher CD. Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases. Am J Surg Pathol 2007; 31:1371.
29. Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 2005; 23:7669.
30. DuBay D, Cimmino V, Lowe L, Johnson TM. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004; 100:1008.
31. Farma JM, Ammori JB, Zager JS, et al. Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol 2010; 17:2112.
32. Cai H, Wang Y, Wu J, Shi Y. Dermatofibrosarcoma protuberans: clinical diagnoses and treatment results of 260 cases in China. J Surg Oncol 2012; 105:142-148.
33. Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous ('high-grade') dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998; 22:576-587. (Pubitemid 28213745)
34. Fields RC, Hameed M, Qin LX, et al. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol 2011; 18:328-336.
35. Ballo MT, Zagars GK, Pisters P, et al. The role of radiation therapy in management of dermatofibrosarcoma protuberans. Int J radiat Oncol Biol Phys 1998; 40:823-827. (Pubitemid 28150799)
36. Haas RL, Keus RB, Loftus BM, et al. The role of radiotheray in local management of dermatofibrosarcoma protuberans. Soft Tissue Tumors Working Group. Eur J Cancer 1997; 33:1055-1060. (Pubitemid 27310781)
37. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of plateletderived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002; 20:3586-3591. (Pubitemid 34983217)
38. Price VE, Fletcher JA, Zielenska M, et al. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer 2005; 44:511-515. (Pubitemid 40614501)
39. Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002; 100:623-626. (Pubitemid 34832970)
40. Labropoulos SV, Fletcher JA, Oliveira AM, et al. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005; 16:461-466. (Pubitemid 40434613)
41. Mizutani K, Tamada Y, Hara K, et al. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004; 151:235-237. (Pubitemid 39061309)
42. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005; 23:866-873. (Pubitemid 46224187)
43. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008; 14:2717-2725.
44. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010; 28:1772-1779.
45. Stacchiotti S, Pedeutour F, Negri T, et al. Dermatofibrosarcoma protuberansderived fibrosarcoma:clinical history, biological profile and sensitivity to imatinib. Int J Cancer 2011; 129:1761-1772.
46. Kerob D, Porcher R, Verola O, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 2010; 16:3288-3295.